目的研究载多柔比星(DOX)的胆固醇修饰乙二醇壳聚糖纳米粒(DCN-16)在荷S180瘤小鼠体内的组织分布。方法将多柔比星和DCN-16分别给动物静脉注射给药,用高效液相色谱法测定荷瘤小鼠不同组织中多柔比星的含量,对药物的体内分布特征和靶向性进行评价。结果DCN-16能够长时间滞留在小鼠血液中,在荷瘤鼠中的心、肺、肾中的血药浓度-时间曲线下面积(AUC0→∞)比多柔比星组显著减小(P<0.05),在肝、脾和肿瘤组织中的AUC0→∞显著增多(P<0.05)。DCN-16在肿瘤中的相对摄取率(Re)为2.56。结论应用胆固醇修饰乙二醇壳聚糖纳米粒负载多柔比星后,能够使药物在血液中长时间循环,增加肿瘤靶向治疗效果和降低心脏的毒副作用。
Abstract
OBJECTIVE To study the tissue distribution of doxorubicin-loaded cholesterol-modified glycol chitosan nanoparticles (named as DCN-16) in S180-bearing mice. METHODS After intravenous administration of doxorubicin (DOX) or DCN-16,DOX concentrations in plasma and tissues samples which were collected at predetermined time were determined by high performance liquid chromatography (HPLC). And DOX distribution and targeting performance in vivo were evaluated. RESULTS DCN-16 displayed long circulation time in S180-bearing mice. The area under the curve (AUC0→∞) of DCN-16 was lower in heart(P<0.05),lung (P<0.05) and kidney(P< 0.05) than that of free DOX. In addition,compared with free DOX,DCN-16 also produced significantly increased drug accumulation in liver(P<0.05),spleen (P<0.05) and tumor(P<0.05). The relative tissue exposure (Re) of DCN-16 in tumor was 2.56-folds of free DOX. CONCLUSION Encapsulating DOX with cholesterol-modified glycol chitosan nanoparticles can prolong the systemic circulation time of DOX,increase its anti-tumor targeting activity and reduce its cardiac toxicity.
关键词
胆固醇修饰乙二醇壳聚糖 /
多柔比星 /
纳米粒 /
组织分布
{{custom_keyword}} /
Key words
cholesterol-modified glycol chitosan /
doxorubicin /
nanoparticle /
tissue distribution
{{custom_keyword}} /
中图分类号:
R944
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] ZHANG C N,WANG W,LIU T,et al.Doxorubicin-loaded glycyrrhetinic acid-modified alginate nanoparticles for liver tumor chemotherapy .Biomaterials,2012,33(7):2187-2196.[2] HUO M R,ZOU A F,YAO C L,et al.Somatostatin receptor-mediated tumor-targeting drug delivery using octreotide-PEG-deoxycholic acid conjugate-modified N-deoxycholic acid-O,N-hydroxyethylation chitosan micelles .Biomaterials,2012,33(27):6393-6407.[3] NIU J X,SU Z G,XIAO Y Y,et al.Octreotide-modified and pH-triggering polymeric micelles loaded with doxorubicin for tumor targeting delivery .Eur J Pharm Sci,2012,45(1-2):216-226.[4] YU J M,LI Y J,QIU L Y,et al.Polymeric nanoparticles of cholesterol-modified glycol chitosan for doxorubicin delivery: Preparation and in-vitro and in-vivo characterization .J Pharm Pharmacol,2009,61(6):713-719.[5] YAN C Y,CHEN D W,GU J W,et al.Nanoparticles of 5-fluorouracil (5-FU) loaded N-succinyl-chitosan (Suc-Chi) for cancer chemotherapy: Preparation,characterization - in-vitro drug release and anti-tumour activity .J Pharm Pharmacol,2006,58(9):1177-1181.[6] COLOMBO P E,BOUSTTA M,POUJOL S,et al.Biodistribution of doxorubicin-alkylated poly(L-lysine citramide imide) conjugates in an experimental model of peritoneal carcinomatosis after intraperitoneal administration .Eur J Pharm Sci,2007,31(1):43-52.[7] HE S M,WEI S L,WU C B,et al.Determination of adriamycin in plasma and liver tissue by HPLC with fluorescence detector .Chin J Pharm Anal(药物分析杂志),1994,14(4):8-11.[8] LI X M,DING L Y,WANG Y L,et al.Pharmacokinetics and tissue distribution of doxorubicin liposomes modified with transferrin .J China Pharm Univ(中国药科大学学报),2009,40(2):120-124.[9] NOGUCHI Y,WU J,DUNCAN R,et al.Early phase tumor accumulation of macromolecules: A great difference in clearance rate between tumor and normal tissues .Japan J Cancer Res,1998,89(3):307-314. MATSUMURA Y,MAEDA H.A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs .Cancer Res,1986,46(12):6387-6392.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}